About
selective inhibitor of protein kinase C beta
Areas of Focus
Categories
Small Molecule PharmaceuticalSan Diego & Southern California
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
112
By Phase
PHASE1/PHASE2: 3PHASE1: 1
By Status
TERMINATED: 2NOT_YET_RECRUITING: 1COMPLETED: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT06979076Lead Sponsor
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL
PHASE1/PHASE2Not yet recruiting
12 participants
Started: Jul 31, 2026 · Completed: Dec 31, 2028
NCT05720052Lead Sponsor
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
PHASE1/PHASE2Terminated
8 participants
Started: Feb 6, 2023 · Completed: Nov 28, 2023
NCT03492125Lead Sponsor
A Study Of The Selective PKC-β Inhibitor MS- 553
PHASE1/PHASE2Terminated
60 participants
Started: May 25, 2018 · Completed: Nov 28, 2023
NCT02406989Lead Sponsor
A Multiple-Ascending Dose Study of MS-553 in Healthy Volunteers
PHASE1Completed
32 participants
Started: Apr 30, 2015 · Completed: Sep 30, 2015
Funding History (1)
D
Nov 22, 2021
Locations (1)
Headquarters
San Diego, CA, United States
Map
Loading map...